IPO 2026
SME IPO
IPO GMP
Subscription
Allotment
Listing

Q-Line Biotech NSE SME IPO review

  • The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
  • It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
  • As the company has no listed peers, it is trying to extract fancy price for its IPO.
  • Based on its overall financial data, the issue appears fully priced.
  • Well-informed investors may park moderate funds for long term.
Dilip Davda

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges. 

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBLā€™s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipmentā€™s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipmentā€™s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipmentā€™s and devices as per the technical collaboration and specifications provided by the partners or companies. 

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Q-Line Biotech IPO

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share.  The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes. 

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM groupā€™s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 ā€“ Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, companyā€™s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr. 

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained. 

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended Revenue Expense PAT Assets
2023 ā‚¹184.81 ā‚¹154.97 ā‚¹32.10 ā‚¹251.58
2024 ā‚¹206.45 ā‚¹175.85 ā‚¹34.44 ā‚¹339.25
2025 ā‚¹322.58 ā‚¹261.43 ā‚¹28.13 ā‚¹455.49
Dec 2025 ā‚¹236.50 ā‚¹186.96 ā‚¹38.69 ā‚¹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects. 

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company Face Value (ā‚¹) EPS basic (ā‚¹)Ā  EPS Diluted (ā‚¹) RONW (%) P/E Ratio NAV (ā‚¹)
Powerica Limited 5 15.26Ā  15.26 15.37 %Ā  24.45 99.76
Listed Peers
Cummins India Limited 2 72.15Ā  72.15 26.45% 64.13Ā  272.78
Kirloskar Oil Engines Limited 2 33.71 33.60 15.85% 43.24 212.60
NTPC Green Energy Limited 10 0.67 0.67 2.58% 129.40 21.88
Acme Solar Holdings Limited 2 4.55 4.53 5.59% 50.74Ā  74.54
Adani Green Energy Limited 10 8.37 8.37 11.90%Ā  101.53Ā  76.62
Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion
Q-Line Biotech IPO FAQs
1. What is Q-Line Biotech IPO? āŒ„
Q-Line Biotech IPO is SME IPO. The company is going to raise ā‚¹214 Crores via IPO. The issue is priced at ā‚¹326 to ā‚¹343 per equity share. The IPO is to be listed on NSE SME.
2. When Q-Line Biotech IPO will open for subscription? āŒ„
The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.
3. What is Q-Line Biotech IPO Investors Portion? āŒ„
The investorsā€™ portion for QIB is 50%, NII is 15%, and Retail is 35%.
4. How to Apply the Q-Line Biotech IPO? āŒ„
You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
5. What is Q-Line Biotech IPO Issue Size? āŒ„
Q-Line Biotech IPO issue size is ā‚¹214 crores.
6. What is Q-Line Biotech IPO Price Band? āŒ„
Q-Line Biotech IPO Price Band is ā‚¹326 to ā‚¹343.
7. What is Q-Line Biotech IPO Lot Size? āŒ„
The minimum bid is 800 Shares with ā‚¹2,74,400 amount.
8. What is the Q-Line Biotech IPO Allotment Date? āŒ„
Q-Line Biotech IPO allotment date is May 26,2026.
9. What is the Q-Line Biotech IPO Listing Date? āŒ„
Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Uniparts India IPO Date, Review, Price, Allotment, Analysis

Join
Follow Us
Add Source
Follow
Apply for an IPO
Uniparts India IPO

Uniparts India IPO date is fixed, the IPO is to hit the market on November 30 and will close on December 2. Uniparts India Technologies IPO to raise around ā‚¹835 crores via IPO that comprises fresh issue of ā‚¹[.] crores and offer for sale up to 14,481,942 equity shares of ā‚¹10 each. The retail quota is 35%, QIB is 50%, and HNI is 15%.

Uniparts India Limited was incorporated in 1994. The company is a manufacturer of engineered systems and solutions based in India. They are the leading supplier of systems and components for the off-highway market. They operate from their Six manufacturing facilities and four warehousing locations across the US, Europe, and India. They are selling their products in 25 countries.

The company provides its products to the sectors like agriculture, construction forestry & mining (CFM), and aftermarket. The product portfolio includes core product verticals of 3-point linkage systems (3PL) and precision machined parts (PMP) as well as adjacent product verticals of power take-off, fabrications, and hydraulic cylinders or components thereof. We serve OHV players including OEMs and aftermarket retail store chains, through our global business model based on our dual-shore integrated manufacturing, warehousing, and supply chain management systems and solutions. Uniparts India has its Registered Office in New Delhi and manufacturing locations in Noida, Ludhiana & Vishakhapatnam. Uniparts India mobilises Rs 251 cr from anchor investors ahead of IPO launch on 30 November, Wednesday.

Important Details

  • Having good presence in India and Outside India in 25 countries.
  • Their 4 Business Models
    • International Sales
    • Local Deliveries
    • Direct Exports
    • Wholesale Sales

Uniparts India IPO Review (Apply or Not)

  • Apply

Brokerage Firm IPO Review

  • BP Equities: Apply
  • Capital Market: May Apply
  • Choice Equity: Apply
  • Hem Securities: Apply
  • Jainam Broking: Apply
  • KR Choksey: Apply
  • Nirmal Bang: Apply
  • Religare Broking: Apply

Uniparts India IPO Date & Price Band Details

IPO Open:November 30, 2022
IPO Close:December 2, 2022
IPO Size:Approx ā‚¹835 Crores
Fresh Issue:Approx ā‚¹[.] Crores
Offer for Sale:Approx 14,481,942 Equity Shares
Face Value:ā‚¹10 Per Equity Share
IPO Price Band:ā‚¹548 to ā‚¹577 Per Share
IPO Listing on:BSE & NSE
Retail Quota:35%
QIB Quota:50%
 NII Quota:15%
Discount:N/A
DRHP Draft Prospectus:Click Here
RHP Draft Prospectus:Click Here
Anchor Investors List:Click Here

Uniparts India IPO Market Lot

The Uniparts India IPO minimum market lot is 25 shares with ā‚¹14,425 application amount. The retail investors can apply up-to 13 lots with 325 shares or ā‚¹187,525 amount.

ApplicationLot SizeSharesAmount
Retail Minimum125ā‚¹14,425
Retail Maximum13325ā‚¹187,525
S-HNI Minimum15350ā‚¹201,950
B-HNI Minimum711750ā‚¹1,009,750

Uniparts India IPO Allotment & Listing Dates

The Uniparts India IPO date is November 30 and the close date is December 2. The Uniparts India IPO allotment will be finalized on December 7 and the IPO listing on December 12.

Price Band Announcement:November 25, 2022
Anchor Investors Allotment:November 29, 2022
IPO Open Date:November 30, 2022
IPO Close Date:December 2, 2022
Basis of Allotment:December 7, 2022
Refunds:December 8, 2022
Credit to Demat Account:December 9, 2022
IPO Listing Date:December 12, 2022

You can check IPO subscription status and IPO allotment status on their respective pages.

Uniparts India IPO Form

How to apply for the Uniparts India IPO? You can apply for Uniparts India IPO via ASBA available in your bank account. Just go to the online bank login and apply via your bank account by selecting the Uniparts India IPO in the Invest section. The other option is you can apply for Uniparts India IPO via IPO forms downloaded via NSE and BSE. Check out the Uniparts India forms – Click BSE Forms & NSE Forms blank IPO forms download, fill, and submit in your bank or with your broker.


Uniparts India Company Financial Report

  ā‚¹ in Crores
YearRevenueExpensePAT
2020ā‚¹939ā‚¹865ā‚¹62.64
2021ā‚¹948ā‚¹829ā‚¹92.39
2022 9Mā‚¹884ā‚¹714ā‚¹12.29

Uniparts India IPO Valuation – FY2021

Check Uniparts India IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.

Earning Per Share (EPS):ā‚¹20.95 per Equity Share
Price/Earning P/E Ratio:N/A
Return on Net Worth (RoNW):16.52%
Net Asset Value (NAV):ā‚¹123.94 per Equity Share

Peer Group

  • N/A

Company Promoters

  • Gurdeep Soni
  • Paramjit Singh Soni

Uniparts India IPO Registrar

Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: uniparts.ipo@linkintime.co.in
Website: https://linkintime.co.in/

Uniparts India IPO Allotment Status Check

Check Uniparts India IPO allotment status on Linkintime website allotment URL. Click Here

Uniparts India IPO Lead Managers

  • Axis Bank Limited
  • DAM Capital Advisors Ltd (Formerly IDFC Securities Ltd)
  • JM Financial Consultants Private Limited

Company Address

Uniparts India Limited
Gripwel House, Block ā€“ 5,
Sector C6 &7, VasantKunj
NewDelhi 110070
Phone: + 91 120 458 1400
Email: compliance.officer@unipartsgroup.com
Website: https://www.unipartsgroup.com/

Uniparts India IPO FAQs

What is Uniparts India IPO?

Uniparts India IPO is a main-board IPO. They are going to raise ā‚¹835 Crores via IPO. The issue is priced at ā‚¹548 to ā‚¹577 pr equity share. The IPO is to be listed on BSE & NSE.

When Uniparts India IPO will open?

The IPO is to open on November 30, 2022 for QIB, NII, and Retail Investors.

What is Uniparts India IPO Investors Portion?

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

How to Apply the Uniparts India IPO?

You can apply for Uniparts India IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

How to Apply the Uniparts India IPO through Zerodha?

Log in to Console in Zerodha Website or in Application. Go to Portfolio and Click on IPO. You will see the IPO Name “Uniparts India”. Click on Bid Button. Enter your UPI ID, Quantity, and Price. Submit IPO Application Form. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Zerodha.

How to Apply the Uniparts India IPO through Upstox?

Log in to the Upstox Application with your credentials. Select the IPO. You will see the IPO Name “Uniparts India”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Upstox.

How to Apply the Uniparts India IPO through Paytm Money?

Log in to Paytm Money Application with your credentials. Select the IPO. You will see the IPO Name “Uniparts India”. Click on Bid Button. Confirm your Application. Now go to your UPI App on Net Banking or BHIM App to Approve the mandate. Open Demat Account with Paytm Money.

What is Uniparts India IPO Size?

Uniparts India IPO size is ā‚¹835 crores.

What is Uniparts India IPO Price Band?

Uniparts India IPO Price Band is ā‚¹548 to ā‚¹577.

What is Uniparts India IPO Minimum and Maximum Lot Size?

The minimum bid is 25 Shares with ā‚¹14,425 amount while the maximum bid is 325 shares with ā‚¹187,525.

What is the Uniparts India IPO Allotment Date?

Uniparts India IPO allotment date is December 7, 2022.

What is the Uniparts India IPO Listing Date?

Uniparts India IPO listing date is December 12, 2022. The IPO is to list on BSE and NSE.

Note: The Uniparts India IPO price band and date are officially announced. The IPO grey market premium (Uniparts India IPO Premium) will be added to the IPO grey market page as it will start).

Follow IPO Watch for the Upcoming IPO news and their reviews, also keep following us on Twitter, Facebook, and Instagram. For our latest videos, subscribe to our YouTube channel.

Table of Contents

Picture of Jagat Joshi

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.
Picture of Jagat Joshi

Jagat Joshi

Add IPOWatch to your Google News feed.   google news button

4 Responses

Current Mainboard IPO

Current SME IPO

Latest IPO News

IMP LINKS

Related Posts

Apply IPO